Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q4 2024 (December 31)15holders −1
2new positions
3sold out
$1.04avg. 13F price*
At the end of Q4 2024, 15 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, down 1 from Q3 2024. 2 opened new positions and 3 sold out. The largest holders were Sonora Investment Management Group, LLC ($3.9M), New York State Common Retirement Fund ($3.6M) and Nomura Holdings Inc. ($795K).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $20K |
| Exits | 3 | $3.1M |
All 13F filers, Q3 2024 → Q4 2024: 351,856 shares bought and 3,602,543 shares sold, net −3,250,687 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Sonora Investment Management Group, LLC | 0.30% | Reduce -0.6% | 4,092,000 | $3.9M |
| New York State Common Retirement Fund | 0.00% | Add +9.3% | 3,761,000 | $3.6M |
| Nomura Holdings Inc. | 0.00% | Add +185.3% | 16,630 | $795K |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 650,000 | $619K |
| Bank of New York Mellon Corp | 0.00% | Reduce -71.4% | 200,000 | $191K |
| Cetera Investment Advisers | 0.00% | Reduce -11.4% | 171,000 | $163K |
| &partners | 0.00% | Add +0.7% | 144,000 | $137K |
| Rollins Financial Advisors, LLC | 0.01% | No change | 54,000 | $52K |
| Mariner, LLC | 0.00% | No change | 54,000 | $51K |
| Choreo, LLC | 0.00% | No change | 47,000 | $45K |
| MAI Capital Management | 0.00% | New | 19,000 | $18K |
| Comerica Bank | 0.00% | No change | 10,000 | $10K |
| Laffer Tengler Investments, Inc. | 0.00% | Add +2.8% | 2,038 | $2K |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 2,000 | $2K |
| Lanark Financial, Inc. | 0.00% | — | 13 | $12 |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.